Fluid restriction for treatment of symptomatic patent ductus arteriosus in preterm infants

Abigale MacLellan, Austin J. Cameron, Chris Cooper, Souvik Mitra*

*Corresponding author for this work

Research output: Contribution to journalProtocol

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the effectiveness and safety of fluid restriction for symptomatic patent ductus arteriosus (PDA) in preterm infants. To determine if fluid restriction (parenterally, enterally, or both) with or without diuretics reduces morbidity and mortality in preterm infants with a symptomatic PDA.

Original languageEnglish
Article numberCD015424
JournalCochrane Database of Systematic Reviews
Volume2022
Issue number12
DOIs
Publication statusPublished - 12 Dec 2022

Bibliographical note

Funding Information:
The methods section of this protocol is based on a standard template used by Cochrane Neonatal. We thank Cochrane Neonatal: Michelle Fiander and Jane Cracknell, Managing Editors; and Co-ordinating Editors Roger Soll and Bill McGuire who provided support. We thank Jonathan Flyer, Assistant Professor, Larner College of Medicine at the University of Vermont, Division of Pediatric Cardiology, Department of Pediatrics for peer review of this manuscript. We thank Victoria Pennick for copy-editing and proofreading this protocol.

Publisher Copyright:
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Fingerprint

Dive into the research topics of 'Fluid restriction for treatment of symptomatic patent ductus arteriosus in preterm infants'. Together they form a unique fingerprint.

Cite this